drugset
drugset / Trial / NCT02222363

Study of Safety and Tolerability of VLX600, an Iron Chelator, in Patients With Refractory Advanced Solid Tumors

NCT02222363 ↗

Phase 1 Terminated 19 enrolled Vivolux AB Theradex · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and tolerability of the investigational drug VLX600 in patients with refractory advanced solid tumors.

Timeline

Start
2015-02-18
Primary completion
2016-12-28
Completion
2016-12-28

Outcome

Outcome not reported

Stopped (Enrollment): “Slow recruitment and lack of efficacy despite the completion of several dose steps.”

Drugs

EvaluationDrugModalityDoseRoute
Subject VLX600 Small molecule 10 mg Intravenous
Subject VLX600 Small molecule 20 mg Intravenous
Subject VLX600 Small molecule 40 mg Intravenous
Subject VLX600 Small molecule 80 mg Intravenous
Subject VLX600 Small molecule 160 mg Intravenous
Subject VLX600 Small molecule 210 mg Intravenous

Indications

refractory malignant neoplasm